[PDF] Top 20 Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
Has 10000 "Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand" found on our website. Below are the top 20 most common "Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand".
Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
... the cost-effectiveness of adjuvant imatinib treat- ment for 3 years with an adjuvant imatinib treatment for 1 ...those cost-effectiveness comparisons was between 3 years ... See full document
12
Original Article Prognostic value of Ki67 index in gastrointestinal stromal tumors
... in GIST patients and efficiency of imatinib adjuvant ...recorders. Recurrence-free survivals (RFS) were evaluated in 418 GIST patients (370 cases only taken the surgery ... See full document
7
<p>Effect of the imatinib treatment regimen on the postoperative prognosis of patients with high-risk gastrointestinal stromal tumors</p>
... for risk classi fi cation assessment was based on tumor site, size and mitotic ...and high mitotic count are associated with poor ...of patients with high-risk GIST improved due ... See full document
7
Update on imatinib for gastrointestinal stromal tumors: duration of treatment
... of GIST and tumors $3 cm in ...and patients started treatment within 84 days of surgery; 713 patients were randomized and assigned to imatinib 400 mg/day or placebo for one ...to ... See full document
13
Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal
... most gastrointestinal stromal tumors (GISTs). GIST has become a model for targeted treatment of solid tumors, imatinib becoming the standard first-line treatment of these tumors ... See full document
7
Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome
... in high-risk cases was significantly higher than that in intermediate-, low- and very low-risk cases, and even in the same high-risk classification, the clinical outcomes of GIST ... See full document
8
Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.
... In patients with resectable localised disease, primary therapy consists of ...For patients with high-risk of recurrence, adjuvant treatment with imatinib is ...that ... See full document
8
Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment
... recurrent GIST could be successfully rescued using ...randomizes patients with intermediate- or high-risk GIST to 2 years of adjuvant IM versus ...IM adjuvant therapy for ... See full document
6
Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)
... Abstract: Gastrointestinal stromal tumors (GISTs), the most common sarcoma of the GI tract, have unique kinase mutations that serve as targets for medical ...(TKI) imatinib in GIST ... See full document
9
UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST)
... in patients with large tumours, because of the risk of tumour rup- ture, which is associated with a very high risk of ...abdomino-perineal resection of rectum, neo- ... See full document
10
Considering the role of radiation therapy for gastrointestinal stromal tumor
... with resection and adjuvant imatinib if at high risk for recurrence, or imatinib alone if ...unresectable. Imatinib has pro- longed the survival of patients ... See full document
6
Segmental resection of the duodenum for gastrointestinal stromal tumor (GIST)
... duodenal GIST. For small tumors, local wedge resection of the duodenum is ...wedge resection instead of gastrectomy seems to be oncologically ...the risk of local recurrence was higher ... See full document
6
Does a glass of Coke boost the exposure to imatinib in gastrointestinal stromal tumour patients after gastrectomy?
... decreased imatinib absorption might be explained by absence of active transporters that are mainly present in the ...Hypothetically, imatinib, like dasatinib absorption is facilitated by these transporters ... See full document
9
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
... local recurrence [17]. Median survival for metastatic GIST patients treated with imatinib has improved to 5 years or more ...observed after imatinib therapy in patients ... See full document
7
Nationwide trends in the incidence and outcome of patients with gastrointestinal stromal tumour in the imatinib era.
... and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials ...in patients with unresectable or metastatic GI stromal tumors: ... See full document
8
The cost utility and budget impact of adjuvant racecadotril for acute diarrhea in children in Thailand
... The cost utility model results show a gain of ...incremental cost to the payer. Although in this analysis there is no notable difference in QoL, there is also no incremental ...a cost ... See full document
12
Hepatic pleomorphic leiomyosarcoma after surgery for gastric gastrointestinal stromal tumor: a case report
... showed a 40-mm-diameter tumor in hepatic segments 3 and 4 (S3 + 4) with an enhanced solid nodule along the wall (Fig. 2). On the right side of the tumor, there was an additional 50-mm tumor, which suggested a hemorrhagic ... See full document
6
Recurrent Giant Phyllodes Tumour of the Breast Pathological Considerations and Management Approach for Recurrence and Metastasis
... the stromal component [3-5]. A benign tumour is characterized by 0 - 4 mitosis/10 high power field (HPF), predominately pushing margin, and usually 1+ but occasionally 2+ stromal ...Borderline ... See full document
6
Neoadjuvant imatinib treatment and laparoscopic anus preserving surgery for a large gastrointestinal stromal tumor of the rectum
... [3]. Imatinib is an inhibitor of tyrosine kinases in- cluding KIT, and targets the aberrant signaling pathways that are critical for tumor cell proliferation and survival, thus showing anti-tumor activity ...of ... See full document
5
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence
... survival analysis was performed (Table 2) that included 21 factors linked to survival: patient age, BMI, underlying liver disease, HBV-DNA, Child-Pugh score, Hb, PLT, creatine, TB, ALB, NLR, total tumor size, ... See full document
10
Related subjects